- Conditions
- Coronary Artery Disease, Clopidogrel, Poor Metabolism of
- Interventions
- Clopidogrel, ticagrelor
- Drug
- Lead sponsor
- First Affiliated Hospital of Harbin Medical University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Havertown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced May 21, 2026, 7:27 PM EDT